Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter M Irving

Showing results (81-90 of 194) with videos related to

Pageof 20
Sort By:
Inflammatory Bowel Diseases|June 23, 2020
Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center ExperienceSailish Honap, Polychronis Pavlidis, Shuvra Ray, et al.
Alimentary Pharmacology & Therapeutics|June 14, 2023
Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndromeBridgette Wilson, Tokuwa Kanno, Rachael Slater, et al.
The Journal of Nutrition|June 29, 2012
Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndromeHeidi M Staudacher, Miranda C E Lomer, Jacqueline L Anderson, et al.
Infectious Disease Reports|January 25, 2022
Recurrent <i>Campylobacter jejuni</i> Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case ReportBlair Merrick, Aravind Gokul Tamilarasan, Raphael Luber, et al.
Inflammatory Bowel Diseases|December 27, 2021
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative ColitisWilliam J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, et al.
BMJ Open Gastroenterology|July 14, 2018
Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)Christopher Sj Probert, Shaji Sebastian, Daniel R Gaya, et al.
Clinical Drug Investigation|April 2, 2023
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical TrialGeert D'Haens, Walter Reinisch, Stefan Schreiber, et al.
Medicine|March 1, 2019
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE studyFraser Cummings, Daniel R Gaya, Scott Levison, et al.
The American Journal of Gastroenterology|May 21, 2020
β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal BifidobacteriaBridgette Wilson, Megan Rossi, Tokuwa Kanno, et al.
Clinical Nutrition (Edinburgh, Scotland)|November 13, 2020
Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probioticsHeidi M Staudacher, Matthias Scholz, Miranda Ce Lomer, et al.
Pageof 20

Showing results (81-90 of 194) with videos related to

Sort By:
Pageof 20
Inflammatory Bowel Diseases|June 23, 2020
Tofacitinib in Acute Severe Ulcerative Colitis-A Real-World Tertiary Center ExperienceSailish Honap, Polychronis Pavlidis, Shuvra Ray, et al.
Alimentary Pharmacology & Therapeutics|June 14, 2023
Faecal and urine metabolites, but not gut microbiota, may predict response to low FODMAP diet in irritable bowel syndromeBridgette Wilson, Tokuwa Kanno, Rachael Slater, et al.
The Journal of Nutrition|June 29, 2012
Fermentable carbohydrate restriction reduces luminal bifidobacteria and gastrointestinal symptoms in patients with irritable bowel syndromeHeidi M Staudacher, Miranda C E Lomer, Jacqueline L Anderson, et al.
Infectious Disease Reports|January 25, 2022
Recurrent <i>Campylobacter jejuni</i> Infection in an Immunodeficient Patient Treated with Repeated Faecal Microbiota Transplant (FMT)-A Case ReportBlair Merrick, Aravind Gokul Tamilarasan, Raphael Luber, et al.
Inflammatory Bowel Diseases|December 27, 2021
Predictors of Sustained Response With Tofacitinib Therapy in Patients With Ulcerative ColitisWilliam J Sandborn, Alessandro Armuzzi, Giuseppina Liguori, et al.
BMJ Open Gastroenterology|July 14, 2018
Golimumab induction and maintenance for moderate to severe ulcerative colitis: results from GO-COLITIS (Golimumab: a Phase 4, UK, open label, single arm study on its utilization and impact in ulcerative Colitis)Christopher Sj Probert, Shaji Sebastian, Daniel R Gaya, et al.
Clinical Drug Investigation|April 2, 2023
Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical TrialGeert D'Haens, Walter Reinisch, Stefan Schreiber, et al.
Medicine|March 1, 2019
A retrospective observational study of early experiences of vedolizumab treatment for inflammatory bowel disease in the UK: The REVIVE studyFraser Cummings, Daniel R Gaya, Scott Levison, et al.
The American Journal of Gastroenterology|May 21, 2020
β-Galactooligosaccharide in Conjunction With Low FODMAP Diet Improves Irritable Bowel Syndrome Symptoms but Reduces Fecal BifidobacteriaBridgette Wilson, Megan Rossi, Tokuwa Kanno, et al.
Clinical Nutrition (Edinburgh, Scotland)|November 13, 2020
Gut microbiota associations with diet in irritable bowel syndrome and the effect of low FODMAP diet and probioticsHeidi M Staudacher, Matthias Scholz, Miranda Ce Lomer, et al.
Pageof 20